nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—HTR2A—phrenic nerve—amyotrophic lateral sclerosis	0.0311	0.142	CbGeAlD
Nefazodone—Uterine leiomyoma—Riluzole—amyotrophic lateral sclerosis	0.0215	0.0291	CcSEcCtD
Nefazodone—Haematocrit decreased—Riluzole—amyotrophic lateral sclerosis	0.0151	0.0204	CcSEcCtD
Nefazodone—Hyperacusis—Riluzole—amyotrophic lateral sclerosis	0.0151	0.0204	CcSEcCtD
Nefazodone—Yawning—Riluzole—amyotrophic lateral sclerosis	0.0139	0.0188	CcSEcCtD
Nefazodone—Paranoid reaction—Riluzole—amyotrophic lateral sclerosis	0.0132	0.0178	CcSEcCtD
Nefazodone—Hernia—Riluzole—amyotrophic lateral sclerosis	0.012	0.0162	CcSEcCtD
Nefazodone—Priapism—Riluzole—amyotrophic lateral sclerosis	0.0116	0.0157	CcSEcCtD
Nefazodone—Muscle relaxant therapy—Riluzole—amyotrophic lateral sclerosis	0.0113	0.0153	CcSEcCtD
Nefazodone—Hypotonia—Riluzole—amyotrophic lateral sclerosis	0.0107	0.0144	CcSEcCtD
Nefazodone—Hostility—Riluzole—amyotrophic lateral sclerosis	0.0101	0.0137	CcSEcCtD
Nefazodone—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.00989	0.0134	CcSEcCtD
Nefazodone—Suicide attempt—Riluzole—amyotrophic lateral sclerosis	0.00989	0.0134	CcSEcCtD
Nefazodone—Completed suicide—Riluzole—amyotrophic lateral sclerosis	0.00955	0.0129	CcSEcCtD
Nefazodone—Enlargement abdomen—Riluzole—amyotrophic lateral sclerosis	0.00933	0.0126	CcSEcCtD
Nefazodone—Myoclonus—Riluzole—amyotrophic lateral sclerosis	0.00933	0.0126	CcSEcCtD
Nefazodone—Libido increased—Riluzole—amyotrophic lateral sclerosis	0.00923	0.0125	CcSEcCtD
Nefazodone—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00884	0.0119	CcSEcCtD
Nefazodone—Tooth disorder—Riluzole—amyotrophic lateral sclerosis	0.00866	0.0117	CcSEcCtD
Nefazodone—Calculus of kidney—Riluzole—amyotrophic lateral sclerosis	0.00857	0.0116	CcSEcCtD
Nefazodone—SLC6A3—nerve—amyotrophic lateral sclerosis	0.00855	0.0392	CbGeAlD
Nefazodone—Paranoia—Riluzole—amyotrophic lateral sclerosis	0.00824	0.0111	CcSEcCtD
Nefazodone—Hyperventilation—Riluzole—amyotrophic lateral sclerosis	0.00816	0.011	CcSEcCtD
Nefazodone—HTR2A—cranial nerve—amyotrophic lateral sclerosis	0.00809	0.037	CbGeAlD
Nefazodone—Depersonalisation—Riluzole—amyotrophic lateral sclerosis	0.00801	0.0108	CcSEcCtD
Nefazodone—HTR2A—pons—amyotrophic lateral sclerosis	0.00799	0.0366	CbGeAlD
Nefazodone—Apathy—Riluzole—amyotrophic lateral sclerosis	0.00786	0.0106	CcSEcCtD
Nefazodone—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.00779	0.0105	CcSEcCtD
Nefazodone—Laryngitis—Riluzole—amyotrophic lateral sclerosis	0.00779	0.0105	CcSEcCtD
Nefazodone—Glaucoma—Riluzole—amyotrophic lateral sclerosis	0.00746	0.0101	CcSEcCtD
Nefazodone—Nephrolithiasis—Riluzole—amyotrophic lateral sclerosis	0.00698	0.00944	CcSEcCtD
Nefazodone—Ageusia—Riluzole—amyotrophic lateral sclerosis	0.00693	0.00937	CcSEcCtD
Nefazodone—SLC6A2—nerve—amyotrophic lateral sclerosis	0.0069	0.0316	CbGeAlD
Nefazodone—HTR2A—hindlimb—amyotrophic lateral sclerosis	0.00682	0.0312	CbGeAlD
Nefazodone—Breast pain—Riluzole—amyotrophic lateral sclerosis	0.00643	0.0087	CcSEcCtD
Nefazodone—SLC6A3—hindbrain—amyotrophic lateral sclerosis	0.0064	0.0293	CbGeAlD
Nefazodone—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.00634	0.00858	CcSEcCtD
Nefazodone—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.00626	0.00846	CcSEcCtD
Nefazodone—ADRA2A—peripheral nervous system—amyotrophic lateral sclerosis	0.00625	0.0286	CbGeAlD
Nefazodone—Ventricular extrasystoles—Riluzole—amyotrophic lateral sclerosis	0.00622	0.0084	CcSEcCtD
Nefazodone—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00617	0.00834	CcSEcCtD
Nefazodone—Thinking abnormal—Riluzole—amyotrophic lateral sclerosis	0.00613	0.00829	CcSEcCtD
Nefazodone—Cough increased—Riluzole—amyotrophic lateral sclerosis	0.00613	0.00829	CcSEcCtD
Nefazodone—Glossitis—Riluzole—amyotrophic lateral sclerosis	0.00609	0.00823	CcSEcCtD
Nefazodone—Nocturia—Riluzole—amyotrophic lateral sclerosis	0.00605	0.00818	CcSEcCtD
Nefazodone—Gout—Riluzole—amyotrophic lateral sclerosis	0.00601	0.00813	CcSEcCtD
Nefazodone—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.00594	0.00802	CcSEcCtD
Nefazodone—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00594	0.00802	CcSEcCtD
Nefazodone—SLC6A4—hindbrain—amyotrophic lateral sclerosis	0.00587	0.0269	CbGeAlD
Nefazodone—HTR2A—appendage—amyotrophic lateral sclerosis	0.00585	0.0268	CbGeAlD
Nefazodone—Gait disturbance—Riluzole—amyotrophic lateral sclerosis	0.00575	0.00777	CcSEcCtD
Nefazodone—Coordination abnormal—Riluzole—amyotrophic lateral sclerosis	0.00572	0.00773	CcSEcCtD
Nefazodone—Neck pain—Riluzole—amyotrophic lateral sclerosis	0.00568	0.00768	CcSEcCtD
Nefazodone—Hiccups—Riluzole—amyotrophic lateral sclerosis	0.00561	0.00759	CcSEcCtD
Nefazodone—Abnormal dreams—Riluzole—amyotrophic lateral sclerosis	0.00555	0.0075	CcSEcCtD
Nefazodone—Urinary incontinence—Riluzole—amyotrophic lateral sclerosis	0.00542	0.00733	CcSEcCtD
Nefazodone—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.00536	0.00724	CcSEcCtD
Nefazodone—HTR2A—peripheral nervous system—amyotrophic lateral sclerosis	0.00532	0.0244	CbGeAlD
Nefazodone—Photophobia—Riluzole—amyotrophic lateral sclerosis	0.00527	0.00712	CcSEcCtD
Nefazodone—HTR1A—hindbrain—amyotrophic lateral sclerosis	0.00521	0.0239	CbGeAlD
Nefazodone—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.00508	0.00686	CcSEcCtD
Nefazodone—Hypertonia—Riluzole—amyotrophic lateral sclerosis	0.00492	0.00665	CcSEcCtD
Nefazodone—Mental disability—Riluzole—amyotrophic lateral sclerosis	0.00487	0.00658	CcSEcCtD
Nefazodone—Euphoric mood—Riluzole—amyotrophic lateral sclerosis	0.00482	0.00652	CcSEcCtD
Nefazodone—ADRA1A—hindbrain—amyotrophic lateral sclerosis	0.0048	0.022	CbGeAlD
Nefazodone—Ear pain—Riluzole—amyotrophic lateral sclerosis	0.00478	0.00646	CcSEcCtD
Nefazodone—Lymphadenopathy—Riluzole—amyotrophic lateral sclerosis	0.00478	0.00646	CcSEcCtD
Nefazodone—Deafness—Riluzole—amyotrophic lateral sclerosis	0.00456	0.00616	CcSEcCtD
Nefazodone—Eczema—Riluzole—amyotrophic lateral sclerosis	0.00453	0.00613	CcSEcCtD
Nefazodone—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00449	0.00607	CcSEcCtD
Nefazodone—Injury—Riluzole—amyotrophic lateral sclerosis	0.00443	0.00599	CcSEcCtD
Nefazodone—Libido decreased—Riluzole—amyotrophic lateral sclerosis	0.00439	0.00594	CcSEcCtD
Nefazodone—Increased appetite—Riluzole—amyotrophic lateral sclerosis	0.00434	0.00586	CcSEcCtD
Nefazodone—Thirst—Riluzole—amyotrophic lateral sclerosis	0.00428	0.00579	CcSEcCtD
Nefazodone—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.00419	0.00567	CcSEcCtD
Nefazodone—HTR2A—nerve—amyotrophic lateral sclerosis	0.00415	0.019	CbGeAlD
Nefazodone—Hyponatraemia—Riluzole—amyotrophic lateral sclerosis	0.00409	0.00553	CcSEcCtD
Nefazodone—Gastrointestinal haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00408	0.00551	CcSEcCtD
Nefazodone—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00408	0.00551	CcSEcCtD
Nefazodone—Diplopia—Riluzole—amyotrophic lateral sclerosis	0.00408	0.00551	CcSEcCtD
Nefazodone—Disturbance in sexual arousal—Riluzole—amyotrophic lateral sclerosis	0.00404	0.00546	CcSEcCtD
Nefazodone—Affect lability—Riluzole—amyotrophic lateral sclerosis	0.00401	0.00542	CcSEcCtD
Nefazodone—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00401	0.00542	CcSEcCtD
Nefazodone—Face oedema—Riluzole—amyotrophic lateral sclerosis	0.00393	0.00532	CcSEcCtD
Nefazodone—Urinary retention—Riluzole—amyotrophic lateral sclerosis	0.00388	0.00524	CcSEcCtD
Nefazodone—Mood swings—Riluzole—amyotrophic lateral sclerosis	0.00386	0.00522	CcSEcCtD
Nefazodone—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.00383	0.00518	CcSEcCtD
Nefazodone—Dehydration—Riluzole—amyotrophic lateral sclerosis	0.00379	0.00512	CcSEcCtD
Nefazodone—Liver function test abnormal—Riluzole—amyotrophic lateral sclerosis	0.00376	0.00509	CcSEcCtD
Nefazodone—Orthostatic hypotension—Riluzole—amyotrophic lateral sclerosis	0.00372	0.00503	CcSEcCtD
Nefazodone—SLC6A3—brainstem—amyotrophic lateral sclerosis	0.00367	0.0168	CbGeAlD
Nefazodone—Aspartate aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00367	0.00496	CcSEcCtD
Nefazodone—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00361	0.00487	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Riluzole—amyotrophic lateral sclerosis	0.00359	0.00486	CcSEcCtD
Nefazodone—HTR2C—brainstem—amyotrophic lateral sclerosis	0.00355	0.0162	CbGeAlD
Nefazodone—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00355	0.00479	CcSEcCtD
Nefazodone—Dysphagia—Riluzole—amyotrophic lateral sclerosis	0.00352	0.00476	CcSEcCtD
Nefazodone—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00352	0.00476	CcSEcCtD
Nefazodone—Asthma—Riluzole—amyotrophic lateral sclerosis	0.00352	0.00476	CcSEcCtD
Nefazodone—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00343	0.00464	CcSEcCtD
Nefazodone—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.00339	0.00458	CcSEcCtD
Nefazodone—SLC6A4—brainstem—amyotrophic lateral sclerosis	0.00336	0.0154	CbGeAlD
Nefazodone—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00329	0.00445	CcSEcCtD
Nefazodone—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00325	0.0044	CcSEcCtD
Nefazodone—Erectile dysfunction—Riluzole—amyotrophic lateral sclerosis	0.00324	0.00438	CcSEcCtD
Nefazodone—Photosensitivity reaction—Riluzole—amyotrophic lateral sclerosis	0.00321	0.00435	CcSEcCtD
Nefazodone—Weight increased—Riluzole—amyotrophic lateral sclerosis	0.00321	0.00433	CcSEcCtD
Nefazodone—Weight decreased—Riluzole—amyotrophic lateral sclerosis	0.00319	0.00431	CcSEcCtD
Nefazodone—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.00316	0.00427	CcSEcCtD
Nefazodone—HTR2A—hindbrain—amyotrophic lateral sclerosis	0.00311	0.0142	CbGeAlD
Nefazodone—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.00306	0.00414	CcSEcCtD
Nefazodone—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00305	0.00413	CcSEcCtD
Nefazodone—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00301	0.00407	CcSEcCtD
Nefazodone—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00299	0.00405	CcSEcCtD
Nefazodone—HTR1A—brainstem—amyotrophic lateral sclerosis	0.00299	0.0137	CbGeAlD
Nefazodone—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.00296	0.004	CcSEcCtD
Nefazodone—SLC6A2—brainstem—amyotrophic lateral sclerosis	0.00296	0.0136	CbGeAlD
Nefazodone—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00295	0.00398	CcSEcCtD
Nefazodone—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00287	0.00388	CcSEcCtD
Nefazodone—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00283	0.00383	CcSEcCtD
Nefazodone—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00283	0.013	CbGeAlD
Nefazodone—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00283	0.00382	CcSEcCtD
Nefazodone—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00282	0.00381	CcSEcCtD
Nefazodone—Hepatitis—Riluzole—amyotrophic lateral sclerosis	0.00282	0.00381	CcSEcCtD
Nefazodone—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00379	CcSEcCtD
Nefazodone—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00281	0.00379	CcSEcCtD
Nefazodone—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.0028	0.00378	CcSEcCtD
Nefazodone—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.00278	0.00375	CcSEcCtD
Nefazodone—ADRA1A—brainstem—amyotrophic lateral sclerosis	0.00275	0.0126	CbGeAlD
Nefazodone—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.00267	0.0036	CcSEcCtD
Nefazodone—ADRA1B—nervous system—amyotrophic lateral sclerosis	0.00257	0.0118	CbGeAlD
Nefazodone—Chills—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00342	CcSEcCtD
Nefazodone—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.00249	0.00337	CcSEcCtD
Nefazodone—HTR2C—medulla oblongata—amyotrophic lateral sclerosis	0.00247	0.0113	CbGeAlD
Nefazodone—ADRA1B—central nervous system—amyotrophic lateral sclerosis	0.00247	0.0113	CbGeAlD
Nefazodone—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00242	0.00327	CcSEcCtD
Nefazodone—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.0024	0.00325	CcSEcCtD
Nefazodone—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00321	CcSEcCtD
Nefazodone—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00236	0.00319	CcSEcCtD
Nefazodone—Tremor—Riluzole—amyotrophic lateral sclerosis	0.0023	0.00311	CcSEcCtD
Nefazodone—SLC6A3—spinal cord—amyotrophic lateral sclerosis	0.00228	0.0104	CbGeAlD
Nefazodone—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00228	0.00308	CcSEcCtD
Nefazodone—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00227	0.00307	CcSEcCtD
Nefazodone—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00226	0.00305	CcSEcCtD
Nefazodone—Angioedema—Riluzole—amyotrophic lateral sclerosis	0.00224	0.00303	CcSEcCtD
Nefazodone—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00221	0.00299	CcSEcCtD
Nefazodone—HTR2C—spinal cord—amyotrophic lateral sclerosis	0.00221	0.0101	CbGeAlD
Nefazodone—Vertigo—Riluzole—amyotrophic lateral sclerosis	0.0022	0.00298	CcSEcCtD
Nefazodone—Syncope—Riluzole—amyotrophic lateral sclerosis	0.0022	0.00297	CcSEcCtD
Nefazodone—Leukopenia—Riluzole—amyotrophic lateral sclerosis	0.0022	0.00297	CcSEcCtD
Nefazodone—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00217	0.00293	CcSEcCtD
Nefazodone—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00216	0.00292	CcSEcCtD
Nefazodone—Cough—Riluzole—amyotrophic lateral sclerosis	0.00214	0.00289	CcSEcCtD
Nefazodone—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00213	0.00287	CcSEcCtD
Nefazodone—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00212	0.00286	CcSEcCtD
Nefazodone—SLC6A4—spinal cord—amyotrophic lateral sclerosis	0.00209	0.00958	CbGeAlD
Nefazodone—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00282	CcSEcCtD
Nefazodone—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00282	CcSEcCtD
Nefazodone—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.00209	0.00282	CcSEcCtD
Nefazodone—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00208	0.00281	CcSEcCtD
Nefazodone—SLC6A2—medulla oblongata—amyotrophic lateral sclerosis	0.00206	0.00945	CbGeAlD
Nefazodone—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00279	CcSEcCtD
Nefazodone—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00276	CcSEcCtD
Nefazodone—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00202	0.00273	CcSEcCtD
Nefazodone—Oedema—Riluzole—amyotrophic lateral sclerosis	0.002	0.00271	CcSEcCtD
Nefazodone—Anaphylactic shock—Riluzole—amyotrophic lateral sclerosis	0.002	0.00271	CcSEcCtD
Nefazodone—Infection—Riluzole—amyotrophic lateral sclerosis	0.00199	0.00269	CcSEcCtD
Nefazodone—Shock—Riluzole—amyotrophic lateral sclerosis	0.00197	0.00266	CcSEcCtD
Nefazodone—ADRA1B—brain—amyotrophic lateral sclerosis	0.00196	0.00898	CbGeAlD
Nefazodone—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00196	0.00265	CcSEcCtD
Nefazodone—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00195	0.00264	CcSEcCtD
Nefazodone—HTR2A—embryo—amyotrophic lateral sclerosis	0.00194	0.00889	CbGeAlD
Nefazodone—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00194	0.00262	CcSEcCtD
Nefazodone—SLC6A3—nervous system—amyotrophic lateral sclerosis	0.00192	0.00881	CbGeAlD
Nefazodone—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.00191	0.00258	CcSEcCtD
Nefazodone—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00187	0.00253	CcSEcCtD
Nefazodone—HTR2C—nervous system—amyotrophic lateral sclerosis	0.00186	0.00851	CbGeAlD
Nefazodone—HTR1A—spinal cord—amyotrophic lateral sclerosis	0.00186	0.0085	CbGeAlD
Nefazodone—SLC6A3—central nervous system—amyotrophic lateral sclerosis	0.00185	0.00848	CbGeAlD
Nefazodone—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00182	0.00247	CcSEcCtD
Nefazodone—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00245	CcSEcCtD
Nefazodone—SLC6A3—cerebellum—amyotrophic lateral sclerosis	0.00181	0.00829	CbGeAlD
Nefazodone—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.0018	0.00243	CcSEcCtD
Nefazodone—HTR2C—central nervous system—amyotrophic lateral sclerosis	0.00179	0.00819	CbGeAlD
Nefazodone—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00179	0.00241	CcSEcCtD
Nefazodone—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00178	0.00241	CcSEcCtD
Nefazodone—HTR2A—brainstem—amyotrophic lateral sclerosis	0.00178	0.00815	CbGeAlD
Nefazodone—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00176	0.00238	CcSEcCtD
Nefazodone—SLC6A4—nervous system—amyotrophic lateral sclerosis	0.00176	0.00807	CbGeAlD
Nefazodone—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.00174	0.00235	CcSEcCtD
Nefazodone—Pain—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00232	CcSEcCtD
Nefazodone—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00232	CcSEcCtD
Nefazodone—SLC6A4—central nervous system—amyotrophic lateral sclerosis	0.0017	0.00777	CbGeAlD
Nefazodone—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00165	0.00223	CcSEcCtD
Nefazodone—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00164	0.00221	CcSEcCtD
Nefazodone—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.00162	0.00742	CbGeAlD
Nefazodone—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00159	0.00215	CcSEcCtD
Nefazodone—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00214	CcSEcCtD
Nefazodone—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00158	0.00214	CcSEcCtD
Nefazodone—HTR1A—nervous system—amyotrophic lateral sclerosis	0.00156	0.00716	CbGeAlD
Nefazodone—Trifluoperazine—SIGMAR1—amyotrophic lateral sclerosis	0.00155	1	CrCbGaD
Nefazodone—SLC6A2—nervous system—amyotrophic lateral sclerosis	0.00155	0.0071	CbGeAlD
Nefazodone—HTR1A—central nervous system—amyotrophic lateral sclerosis	0.00151	0.0069	CbGeAlD
Nefazodone—SLC6A2—central nervous system—amyotrophic lateral sclerosis	0.00149	0.00684	CbGeAlD
Nefazodone—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.00148	0.00199	CcSEcCtD
Nefazodone—HTR1A—cerebellum—amyotrophic lateral sclerosis	0.00147	0.00674	CbGeAlD
Nefazodone—SLC6A3—brain—amyotrophic lateral sclerosis	0.00147	0.00673	CbGeAlD
Nefazodone—ADRA2A—medulla oblongata—amyotrophic lateral sclerosis	0.00146	0.00668	CbGeAlD
Nefazodone—ADRA1A—nervous system—amyotrophic lateral sclerosis	0.00144	0.0066	CbGeAlD
Nefazodone—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00144	0.00194	CcSEcCtD
Nefazodone—HTR2C—brain—amyotrophic lateral sclerosis	0.00142	0.00651	CbGeAlD
Nefazodone—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00142	0.00192	CcSEcCtD
Nefazodone—ADRA1A—central nervous system—amyotrophic lateral sclerosis	0.00139	0.00636	CbGeAlD
Nefazodone—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00137	0.00185	CcSEcCtD
Nefazodone—ADRA1A—cerebellum—amyotrophic lateral sclerosis	0.00136	0.00621	CbGeAlD
Nefazodone—SLC6A4—brain—amyotrophic lateral sclerosis	0.00135	0.00617	CbGeAlD
Nefazodone—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00132	0.00179	CcSEcCtD
Nefazodone—ADRA2A—spinal cord—amyotrophic lateral sclerosis	0.0013	0.00596	CbGeAlD
Nefazodone—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00127	0.00172	CcSEcCtD
Nefazodone—ABCB1—embryo—amyotrophic lateral sclerosis	0.00127	0.00583	CbGeAlD
Nefazodone—Rash—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00171	CcSEcCtD
Nefazodone—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00126	0.00171	CcSEcCtD
Nefazodone—Headache—Riluzole—amyotrophic lateral sclerosis	0.00125	0.0017	CcSEcCtD
Nefazodone—HTR2A—medulla oblongata—amyotrophic lateral sclerosis	0.00124	0.00568	CbGeAlD
Nefazodone—HTR1A—brain—amyotrophic lateral sclerosis	0.0012	0.00548	CbGeAlD
Nefazodone—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00119	0.00161	CcSEcCtD
Nefazodone—SLC6A2—brain—amyotrophic lateral sclerosis	0.00119	0.00543	CbGeAlD
Nefazodone—HTR2A—spinal cord—amyotrophic lateral sclerosis	0.00111	0.00507	CbGeAlD
Nefazodone—ADRA1A—brain—amyotrophic lateral sclerosis	0.0011	0.00505	CbGeAlD
Nefazodone—ADRA2A—nervous system—amyotrophic lateral sclerosis	0.0011	0.00502	CbGeAlD
Nefazodone—ADRA2A—central nervous system—amyotrophic lateral sclerosis	0.00106	0.00483	CbGeAlD
Nefazodone—ADRA2A—cerebellum—amyotrophic lateral sclerosis	0.00103	0.00473	CbGeAlD
Nefazodone—HTR2A—nervous system—amyotrophic lateral sclerosis	0.000932	0.00427	CbGeAlD
Nefazodone—HTR2A—central nervous system—amyotrophic lateral sclerosis	0.000898	0.00411	CbGeAlD
Nefazodone—HTR2A—cerebellum—amyotrophic lateral sclerosis	0.000877	0.00402	CbGeAlD
Nefazodone—CYP3A4—nervous system—amyotrophic lateral sclerosis	0.000863	0.00395	CbGeAlD
Nefazodone—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000849	0.00389	CbGeAlD
Nefazodone—ADRA2A—brain—amyotrophic lateral sclerosis	0.000838	0.00384	CbGeAlD
Nefazodone—CYP3A4—central nervous system—amyotrophic lateral sclerosis	0.000831	0.00381	CbGeAlD
Nefazodone—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.000818	0.00374	CbGeAlD
Nefazodone—ABCB1—medulla oblongata—amyotrophic lateral sclerosis	0.000813	0.00372	CbGeAlD
Nefazodone—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000799	0.00366	CbGeAlD
Nefazodone—ABCB1—spinal cord—amyotrophic lateral sclerosis	0.000725	0.00332	CbGeAlD
Nefazodone—HTR2A—brain—amyotrophic lateral sclerosis	0.000713	0.00326	CbGeAlD
Nefazodone—CYP2D6—brain—amyotrophic lateral sclerosis	0.000649	0.00297	CbGeAlD
Nefazodone—ABCB1—nervous system—amyotrophic lateral sclerosis	0.000611	0.0028	CbGeAlD
Nefazodone—ABCB1—central nervous system—amyotrophic lateral sclerosis	0.000588	0.00269	CbGeAlD
Nefazodone—ABCB1—cerebellum—amyotrophic lateral sclerosis	0.000575	0.00263	CbGeAlD
Nefazodone—ABCB1—brain—amyotrophic lateral sclerosis	0.000467	0.00214	CbGeAlD
Nefazodone—ADRA2A—Metabolism—VAPA—amyotrophic lateral sclerosis	5.92e-05	0.00147	CbGpPWpGaD
Nefazodone—ADRA1A—AMPK Signaling—TP53—amyotrophic lateral sclerosis	5.82e-05	0.00145	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	5.59e-05	0.00139	CbGpPWpGaD
Nefazodone—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	5.5e-05	0.00137	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.5e-05	0.00137	CbGpPWpGaD
Nefazodone—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	5.43e-05	0.00135	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—VAPA—amyotrophic lateral sclerosis	5.42e-05	0.00135	CbGpPWpGaD
Nefazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	5.4e-05	0.00134	CbGpPWpGaD
Nefazodone—HTR2C—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	5.38e-05	0.00134	CbGpPWpGaD
Nefazodone—ADRA2A—G alpha (i) signalling events—C3—amyotrophic lateral sclerosis	5.34e-05	0.00133	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	5.33e-05	0.00133	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	5.3e-05	0.00132	CbGpPWpGaD
Nefazodone—ABCB1—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	5.23e-05	0.0013	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—FIG4—amyotrophic lateral sclerosis	5.17e-05	0.00129	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	5.17e-05	0.00129	CbGpPWpGaD
Nefazodone—ADRA1B—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	5.15e-05	0.00128	CbGpPWpGaD
Nefazodone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	5.13e-05	0.00128	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	5.07e-05	0.00126	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—SACM1L—amyotrophic lateral sclerosis	5.04e-05	0.00125	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	4.93e-05	0.00123	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.84e-05	0.0012	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	4.83e-05	0.0012	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.81e-05	0.0012	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	4.74e-05	0.00118	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—FIG4—amyotrophic lateral sclerosis	4.74e-05	0.00118	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—DAO—amyotrophic lateral sclerosis	4.68e-05	0.00116	CbGpPWpGaD
Nefazodone—HTR2A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	4.67e-05	0.00116	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	4.67e-05	0.00116	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.61e-05	0.00115	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	4.6e-05	0.00115	CbGpPWpGaD
Nefazodone—ADRA1A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	4.57e-05	0.00114	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	4.51e-05	0.00112	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PLB1—amyotrophic lateral sclerosis	4.49e-05	0.00112	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—TPK1—amyotrophic lateral sclerosis	4.47e-05	0.00111	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—VAPB—amyotrophic lateral sclerosis	4.47e-05	0.00111	CbGpPWpGaD
Nefazodone—ABCB1—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	4.44e-05	0.0011	CbGpPWpGaD
Nefazodone—ADRA2A—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	4.32e-05	0.00107	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—DAO—amyotrophic lateral sclerosis	4.29e-05	0.00107	CbGpPWpGaD
Nefazodone—ADRA2A—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	4.25e-05	0.00106	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	4.22e-05	0.00105	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	4.22e-05	0.00105	CbGpPWpGaD
Nefazodone—SLC6A4—Circadian rythm related genes—TP53—amyotrophic lateral sclerosis	4.2e-05	0.00104	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	4.19e-05	0.00104	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.18e-05	0.00104	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GSR—amyotrophic lateral sclerosis	4.15e-05	0.00103	CbGpPWpGaD
Nefazodone—HTR1A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	4.12e-05	0.00102	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	4.1e-05	0.00102	CbGpPWpGaD
Nefazodone—HTR2C—GPCR ligand binding—C3—amyotrophic lateral sclerosis	4.09e-05	0.00102	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	4.09e-05	0.00102	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—VAPA—amyotrophic lateral sclerosis	4.09e-05	0.00102	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	3.97e-05	0.000987	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	3.97e-05	0.000987	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.92e-05	0.000975	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	3.86e-05	0.000959	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.8e-05	0.000946	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	3.8e-05	0.000946	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.77e-05	0.000938	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.75e-05	0.000933	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—SOD1—amyotrophic lateral sclerosis	3.65e-05	0.000908	CbGpPWpGaD
Nefazodone—CYP3A4—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	3.6e-05	0.000895	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.59e-05	0.000894	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	3.58e-05	0.000892	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—FIG4—amyotrophic lateral sclerosis	3.58e-05	0.00089	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.56e-05	0.000884	CbGpPWpGaD
Nefazodone—CYP3A4—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	3.55e-05	0.000883	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.55e-05	0.000882	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PLB1—amyotrophic lateral sclerosis	3.55e-05	0.000882	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	3.54e-05	0.00088	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.53e-05	0.000878	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.48e-05	0.000866	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CHAT—amyotrophic lateral sclerosis	3.41e-05	0.000847	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.38e-05	0.00084	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	3.37e-05	0.000839	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	3.36e-05	0.000836	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	3.35e-05	0.000835	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VCP—amyotrophic lateral sclerosis	3.34e-05	0.000832	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	3.27e-05	0.000814	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GSR—amyotrophic lateral sclerosis	3.27e-05	0.000814	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.26e-05	0.000811	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	3.26e-05	0.00081	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PLB1—amyotrophic lateral sclerosis	3.25e-05	0.000808	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	3.24e-05	0.000806	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—DAO—amyotrophic lateral sclerosis	3.23e-05	0.000805	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—C3—amyotrophic lateral sclerosis	3.23e-05	0.000805	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VCP—amyotrophic lateral sclerosis	3.2e-05	0.000796	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	3.19e-05	0.000794	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	3.1e-05	0.000771	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3.06e-05	0.000762	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	3.05e-05	0.000758	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	3e-05	0.000746	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GSR—amyotrophic lateral sclerosis	3e-05	0.000746	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	2.96e-05	0.000737	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.9e-05	0.000722	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.89e-05	0.000719	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.88e-05	0.000715	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.86e-05	0.000711	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.84e-05	0.000707	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.84e-05	0.000707	CbGpPWpGaD
Nefazodone—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	2.82e-05	0.000701	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.81e-05	0.0007	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	2.79e-05	0.000693	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	2.78e-05	0.000692	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—VAPB—amyotrophic lateral sclerosis	2.76e-05	0.000686	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TPK1—amyotrophic lateral sclerosis	2.76e-05	0.000686	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.75e-05	0.000685	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.75e-05	0.000685	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.72e-05	0.000677	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CHAT—amyotrophic lateral sclerosis	2.69e-05	0.000668	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VCP—amyotrophic lateral sclerosis	2.64e-05	0.000657	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	2.58e-05	0.000642	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	2.56e-05	0.000637	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—VAPA—amyotrophic lateral sclerosis	2.52e-05	0.000627	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.5e-05	0.000621	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.47e-05	0.000614	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CHAT—amyotrophic lateral sclerosis	2.46e-05	0.000612	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PLB1—amyotrophic lateral sclerosis	2.45e-05	0.00061	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.45e-05	0.000608	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.42e-05	0.000602	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.39e-05	0.000595	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.38e-05	0.000591	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.34e-05	0.000583	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	2.33e-05	0.000579	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	2.31e-05	0.000576	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	2.31e-05	0.000575	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.28e-05	0.000566	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	2.27e-05	0.000565	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSR—amyotrophic lateral sclerosis	2.26e-05	0.000563	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	2.25e-05	0.000559	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—IGF1—amyotrophic lateral sclerosis	2.23e-05	0.000554	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	2.21e-05	0.000551	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—FIG4—amyotrophic lateral sclerosis	2.2e-05	0.000548	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.19e-05	0.000545	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	2.13e-05	0.00053	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.11e-05	0.000525	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.1e-05	0.000523	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.06e-05	0.000514	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	2.02e-05	0.000503	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—C3—amyotrophic lateral sclerosis	2.01e-05	0.0005	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	2.01e-05	0.0005	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—DAO—amyotrophic lateral sclerosis	1.99e-05	0.000496	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.97e-05	0.000489	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.96e-05	0.000489	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.95e-05	0.000486	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	1.88e-05	0.000467	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.87e-05	0.000465	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.86e-05	0.000462	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.84e-05	0.000458	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.83e-05	0.000456	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.83e-05	0.000455	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	1.83e-05	0.000455	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.82e-05	0.000454	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.79e-05	0.000444	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.75e-05	0.000436	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.75e-05	0.000436	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	1.75e-05	0.000436	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.75e-05	0.000434	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.7e-05	0.000422	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.68e-05	0.000418	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.67e-05	0.000416	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.66e-05	0.000413	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—C3—amyotrophic lateral sclerosis	1.66e-05	0.000413	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	1.66e-05	0.000412	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.59e-05	0.000396	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.56e-05	0.000388	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	1.54e-05	0.000384	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.52e-05	0.000377	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PLB1—amyotrophic lateral sclerosis	1.51e-05	0.000376	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.5e-05	0.000374	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.49e-05	0.000372	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.48e-05	0.000369	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—VEGFA—amyotrophic lateral sclerosis	1.45e-05	0.000362	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	1.45e-05	0.00036	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.44e-05	0.000359	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.43e-05	0.000356	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.41e-05	0.000351	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.4e-05	0.000349	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSR—amyotrophic lateral sclerosis	1.39e-05	0.000347	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—APOE—amyotrophic lateral sclerosis	1.38e-05	0.000344	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	1.38e-05	0.000343	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.34e-05	0.000334	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.33e-05	0.00033	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.32e-05	0.000329	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.3e-05	0.000323	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.27e-05	0.000316	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.25e-05	0.00031	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.24e-05	0.000309	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.22e-05	0.000303	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.22e-05	0.000303	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.19e-05	0.000297	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.19e-05	0.000296	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	1.18e-05	0.000294	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.16e-05	0.000289	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.16e-05	0.000287	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CHAT—amyotrophic lateral sclerosis	1.14e-05	0.000285	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	1.11e-05	0.000276	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.11e-05	0.000275	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TP53—amyotrophic lateral sclerosis	1.1e-05	0.000273	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—APOE—amyotrophic lateral sclerosis	1.09e-05	0.000272	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.08e-05	0.000268	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.06e-05	0.000263	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1e-05	0.00025	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—APOE—amyotrophic lateral sclerosis	1e-05	0.000249	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.98e-06	0.000248	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.83e-06	0.000244	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.81e-06	0.000244	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.6e-06	0.000239	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.55e-06	0.000238	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.48e-06	0.000236	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	9.41e-06	0.000234	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	9.18e-06	0.000228	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	9.14e-06	0.000227	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOE—amyotrophic lateral sclerosis	9.13e-06	0.000227	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	8.65e-06	0.000215	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.29e-06	0.000206	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	8.12e-06	0.000202	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOE—amyotrophic lateral sclerosis	7.55e-06	0.000188	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.54e-06	0.000188	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—amyotrophic lateral sclerosis	7.48e-06	0.000186	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.39e-06	0.000184	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.35e-06	0.000183	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	7.11e-06	0.000177	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	7.04e-06	0.000175	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.98e-06	0.000174	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.95e-06	0.000173	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.86e-06	0.000171	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.65e-06	0.000165	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.38e-06	0.000159	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.27e-06	0.000156	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	6.25e-06	0.000155	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.24e-06	0.000155	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.15e-06	0.000153	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	6.03e-06	0.00015	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.97e-06	0.000149	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.91e-06	0.000147	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.81e-06	0.000144	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.65e-06	0.000141	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.49e-06	0.000137	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.42e-06	0.000135	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	5.3e-06	0.000132	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.17e-06	0.000129	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.93e-06	0.000123	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	4.87e-06	0.000121	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.74e-06	0.000118	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.71e-06	0.000117	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOE—amyotrophic lateral sclerosis	4.65e-06	0.000116	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.51e-06	0.000112	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.09e-06	0.000102	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	4.01e-06	9.97e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.72e-06	9.26e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.19e-06	7.93e-05	CbGpPWpGaD
